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Matrix Metalloproteinase and Tissue Inhibitor Expression in Athero-
sclerotic and Non-Atherosclerotic Thoracic Aortic Aneurysm
Schmoker JD, McPartland KJ, Fellinger EK, et al. J Thorac Cardiovasc Surg
2007;133:155-61.
Conclusion: Tissue inhibitor/metalloproteinase phenotypes of ath-
erosclerotic thoracic aneurysms (TA) are similar to those of abdominal aortic
aneurysms (AAA).
Summary: It is felt an imbalance of the equilibrium between matrix
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases
(TIMPs) can contribute to the formation of an AAA. Whereas atheroscle-
rotic TAs have similar histologic features as AAAs, many TAs are not
atherosclerotic in origin and are characterized more by extensive cystic
medial necrosis rather than the chronic, inflammatory cell infiltrate more
commonly found in atherosclerotic aneurysms.
It is known altered expressions of MMPs and their TIMPs influence
formation of atherosclerotic aneurysms in the abdominal aorta. In this
study, the authors sought to determine the expression of MMPs and
TIMPs in both nonatherosclerotic and atherosclerotic TAs. Comparisons
were also made with a set of age-matched controls. MMP-2 and -9
activities were measured with antibody capture, and TIMP-1 and -2
levels were measured by enzyme-linked immunosorbent assay. There
were 24 atherosclerotic aneurysms studied, 63 nonatherosclerotic aneu-
rysms, and 17 controls. Gene expression was assessed with reverse
transcriptase polymerase chain reaction.
All data are expressed in nanograms per milligram of protein. MMP
levels in controls, atherosclerotic, and nonatherosclerotic groups were 80
7, 49 50, and 35 44, (P .002). In the atherosclerotic group, MMP-9
activity was greater than in the nonatherosclerotic group and controls (11.7
 15.7 vs 2.5 2.2 vs 1.7 1.9, P .001). In the control group, TIMP-1
and -2 levels were greater than in either aneurysm group. TIMP-1 levels
were 376 192 vs 234 233 vs 174 148 (P .003), and TIMP-2 levels
were 143  74 vs  13 vs 27  43 in the control, atherosclerotic, and
nonatherosclerotic groups, respectively (P  .001). MMP messenger RNA
was expressed to a greater degree in atherosclerotic aneurysms than in
controls.
Comment:Not surprisingly, MMP-9 levels were higher in atheroscle-
rotic TAs than in controls and nonatherosclerotic TAs. The authors also
noted regional differences in MMP activity levels, with ascending athero-
sclerotic TAs having higher total MMP-2 activity than descending athero-
sclerotic TAs. They postulate reduced MMP-2 activity and TIMP protein
gene expression in nonatherosclerotic TAs compared with controls may
reflect dysfunction of smooth muscle cells with respect to their ability to
compensate for age-related hemodynamic stresses.
Antithrombotic Therapy and Endovascular Stents Are Effective Treat-
ment for Blunt Carotid Injuries: Results From Long-Term Follow-up
Edwards NM, Fabian TC, Claridge JA. J Am Coll Surg 2007;204:1007-15.
Conclusions: In the long term, anticoagulation and antiplatelet ther-
apies are equally effective in preventing cerebral infarction after blunt carotid
injury (BCI). In patients with pseudoaneurysms or extensive dissections,
carotid stents appear to be safe and effective.
Summary: Heparin has traditionally been used to reduce stroke rates
after BCI, especially carotid dissection. Antiplatelet therapy (aspirin or
clopidogrel, or both) is now considered alternative therapy to anticoagula-
tion but does not have proven efficacy. About 13% of BCIs are associated
with pseudoaneurysms. Carotid stenting has been used for treatment of such
lesions. Results have been mixed, with both positive (J Trauma 2000;48:
470-2) and negative results (Arch Surg 2005;140:480-5). This article
sought to address the long-term efficacy of antiplatelet and anticoagulation
therapy, and carotid stents in the treatment of BCI.
The authors followed up consecutive patients treated for BCI at a single
trauma center from 1996 through 2005. Outcomes evaluated included
cerebral infarction, functional status, and angiographic evolution of the
lesion.
During the study period, 110 patients were diagnosed with 133
BCIs. Mortality was 26%, with 6% of the mortality directly attributed to
the BCI. Angiographic follow-up was available in 50 patients (67 inju-
ries) at a mean of 6 months after injury (range, 0.25 to 67 months). Of
these visualized injuries, 75% remained the same or improved. Clinical
follow-up was available in 55 of 81 patients (68%) who survived to
discharge. Mean follow-up was 34.4 months (range, 1 to 109 months).
Of the surviving patients, 44% were treated with antiplatelet therapy, 49%
with anticoagulation, and 7% were treated with both. There were no
episodes of cerebral infarction after discharge and no difference in
functional outcome based on the use of anticoagulant vs antiplatelet
therapy. A total of 22 endovascular stents were placed: 18 for pseudoan-
eurysm and four for extensive dissection. The mean follow-up of these
patients was 29.7 months (range, 3 to 94 months). No patients who
received a stent experienced periprocedural complications. One patient
with an associated brain injury had a cerebral infarct.
Comment: The data here are obviously incomplete and do not settle
the controversy of anticoagulant vs antiplatelet therapy for BCI. Either
therapy appears effective. Only a randomized trial will settle the issue. A
widely publicized previous study criticizing carotid stents for treatment of
pseudoaneurysms or dissections after BCI was published before widespread
use of antiplatelet therapy in conjunction with carotid stents. It may be that
the improved results with carotid stents in this report are because almost all
of the patients treated with carotid stents for BCI in this series were also
treated with antiplatelet therapy.
High-Density Lipoprotein and the Risk of Recurrent Venous
Thromboembolism
Eichinger S, Pecheniuk NM,Hron G, et al. Circulation 2007;115:1609-14.
Conclusion: High levels of apolipoprotein A1 and high-density li-
poprotein (HDL) decrease the risk of recurrent venous thromboembolism
(VTE).
Summary:HDL acts as a relative protector against atherosclerosis. The
authors sought to determine whether HDL levels also protect against
recurrent VTE. The study cohort comprised 772 patients with a first episode
of spontaneous VTE. The average follow-up was 48 months. The end point
was symptomatic recurrent VTE, which developed in 100 of the 772
patients. The authors then sought to evaluate levels of plasma lipoproteins in
recurrence of VTE. Apolipoproteins A1 and B were measured by immuno-
assay.
Patients with recurrent VTE had lower levels, mean  standard
deviation, of apolipoprotein A1 (1.12  0.22 vs 1.23  0.27 mg/mL, P
 .001). They had similar apolipoprotein B levels. Relative risk of
recurrence of VTE was 0.87 (95% confidence interval [CI], 0.80 to 0.94)
for each increase of 0.1 mg/mL of plasma apolipoprotein A1. Patients
with apolipoprotein AI levels in the lowest tertial (1.07 mg/mL) had a
relative risk of 0.46 (95% CI, 0.27 to 0.77) compared with the highest
tertial patients (apolipoprotein A1 1.30 mg/mL). Patients in the
lowest tertial of apolipoprotein A1 levels had a relative risk of 0.78 (95%
CI, 0.50 to 1.22) compared with the middle tertial patients (apolipopro-
tein A1 levels of 1.07 to 1.30 mg/mL). Nuclear magnetic resonance was
used to analyze levels of 10 major lipoprotein subclasses and HDL. There
was a strong trend for recurrence of VTE with low levels of HDL particles
and HDL cholesterol.
Comment: Apolipoprotein A1 is the major protein component of
HDL cholesterol. Given the prospective nature of this study, it provides
strong evidence for protection against risk of recurrent VTE by increased
levels of HDL cholesterol. Metabolism of HDL is complex, but it does
appear to have some antithrombotic properties. HDL can down-regulate
thrombin and act directly on endothelium to minimize peripheral throm-
botic reactions. Because women with VTE have higher levels of HDL than
men, the findings in the current study may partially explain the higher
recurrence rate for VTE in male vs female patients (N Engl J Med 2004;
350:2558-63).
Patient Fitness and Survival After Abdominal Aortic Aneurysm Repair
in Patients from the UK EVAR Trials
The EVAR Trial participants. Br J Surg 2007;94:709-16.
Conclusion: Endovascular repair has greatest benefit in the fittest
patients. There is no evidence that fitter patients benefit from open
surgery compared with endovascular repair of an abdominal aortic aneu-
rysm (AAA).
Summary: The authors sought to determine whether fitter patients with
large AAAs would have greater benefit from open rather than endovascular
repair. The authors used the customized probability index (CPI) in this study.
CPI is one of several preoperative fitness scoring systems that has been devel-
oped and validated. CPI evaluates measures of cardiovascular disease, treat-
ments for hypertension, respiratory dysfunction, renal dysfunction, and medi-
cation use, including -blockers and statins. Patients receive positive points for
indicators of poor fitness and negative points for indicators of better fitness.
Possible scores range from a –25 (good fitness) to57 (poor fitness).
823
CPI was applied to patients in the Endovascular Aneurysm Repair
(EVAR) I and II trials. The effect of fitness and type of AA repair was
determined with respect to elective 30-day mortality and 4-year survival.
The mean (SD) CPI scores were 3.6 (9.3) for 1252 EVAR I patients
and 10.0 (11.3) for 404 EVAR II patients; range –25 to43 (P .001). Of
these, 579 EVAR I patients were classified as good fitness (mean CPI, –4.2),
331 were classified as moderate fitness (mean CPI, 5.7), and 338 patients
were classified as poor fitness (mean CPI, 15.1). Only in the good fitness
group did 30-day mortality convincingly favor endovascular repair (odds
ratio, 0.24; P  .030). The overall test of interaction was not significant (P
 .363). For 4-year all-cause and aneurysm-related mortality, there was no
benefit for either treatment across all fitness scores (P  .281 and P  .371
respectively).
Comment: It is a little surprising and somewhat counterintuitive
that sustained benefit for aneurysm-related mortality in EVAR patients
was most convincing in the fittest patients. However, the number of
deaths 30 days in the EVAR patients (10 of 610) and patients under-
going open repair (25 of 596) was small. This makes precise and
dogmatic interpretation of the data somewhat difficult. However, as the
authors point out, the data certainly do not allow one to conclude that
fitter patients benefit from open surgery compared with EVAR. In fact,
the opposite may be true.
Final Twelfth-Year Follow-up of Surgery vs Surveillance in the UK
Small Aneurysm Trial
UK Small Aneurysm Trial Participants. Br J Surg 2007;94:702-8.
Conclusion: There is no long-term survival benefit of early elective
open repair of small abdominal aortic aneurysms (AAAs). Patients still have
higher mortality rates after successful AAA repair than the general popula-
tion.
Summary: This represents the final follow-up of the UK Small Aneu-
rysm Trial. The trial was designed to determine whether early open surgical
repair benefited patients with small AAAs. The UK Small Aneurysm Trial
randomized 1276 patients between the ages of 60 and 76 years who were
considered fit for surgery to immediate repair of an infrarenal AAA between
4.0 and 5.5 cm or ultrasound surveillance. Aneurysms in the surveillance
group were repaired once they reached a diameter 5.5 cm, became
symptomatic, or demonstrated a worrisome growth rate.
Of the 1276 patients identified and potentially eligible for the study,
1090 patients were enrolled between 1991 and 1995. They were fol-
lowed up for aneurysm repair and mortality until November 2005. By
November 2005, 65.5% of the patients (n  714) had died, 85.2% had
undergone aneurysm repair, 13.8% (n  150) died without aneurysm
repair, and 1% were still alive without aneurysm repair. Overall mortality
was 63.9% in the surgery group and 67.3% in the surveillance group
(unadjusted hazard ratio, 0.90; P  .139). Three-fourths of the patients
in the surveillance group eventually had aneurysm repair. The 30-day
mortality rate for elective repair was 6.3% in the surveillance group and
5.0% in the early surgery group (P  .366). Cost estimates suggest a 17%
higher cost in the early surgery group. The death rate of patients in the
UK Small Aneurysm Trial was about twice that of the population
matched for age and sex.
Comment: The UK Small Aneurysm Trial and others had already
proven that early open repair of small AAAs has no early survival benefit.
There is now clearly no late survival benefit, either. Given the high rate of
mortality in AAA patients compared with the general population, perhaps
the greatest benefit of AAA screening will be the identification of another
group of patients who should be targeted for vigorous cardiovascular
risk-factor reduction.
Outcome Following Bypass and Proximal and Distal Ligation of Pop-
liteal Aneurysms
Box B, Adamson M, Magee TR. Br J Surg 2007;94:179-82.
Conclusion: Treatment of popliteal aneurysms with proximal and
distal ligation and intervening bypass produces excellent long-term patency
and exclusion of the popliteal aneurysm.
Summary: Ligation of popliteal aneurysms should exclude them from
the circulation. Recent studies have suggested, however, that one-third of
popliteal aneurysms treated by bypass and ligation/exclusion can develop or
retain flow after operation (J Vasc Surg 2003;37:958-59, Br J Surg 2004;
91:174-7). Nevertheless, proximal and distal ligation and bypass have re-
mained the standard for treatment of popliteal aneurysms.
The authors identified 116 patients with popliteal aneurysms, 66 of
whom were treated with bypass and ligation. Postoperative graft patency
was determined by duplex surveillance. Seventeen patients with bypassed
popliteal arteries underwent 33 duplex scans to examine for persistent
flow within the aneurysm sac and an increase in size of the popliteal
aneurysm.
When the popliteal artery was patent preoperatively, 3-, 5-, and 8-year
primary patency rates for bypass grafting were 78%, 78%, and 51%, respec-
tively. The rates did not differ from those obtained after bypass for throm-
bosed popliteal aneurysms, with 3- and 5-year primary patency being 72%
and 65%. In this study, no popliteal aneurysm produced further symptoms
after bypass and ligation. Duplex imaging did not reveal any flow in any
bypassed and excluded popliteal aneurysm during follow-up. One aneurysm
did show an increase in size.
Comment: The authors’ data contrast with recent studies suggest-
ing residual flow within the popliteal aneurysm and aneurysm growth in
some patients after proximal and distal ligation and intervening bypass
for popliteal aneurysm. It is unclear why their observations differ from
other recent studies. The authors suggest that the proximal and distal
sites of ligation be as close as possible to the popliteal aneurysm. Only a
few of their patients received follow-up imaging; therefore, the true
incidence of maintained patency of the popliteal aneurysm cannot be
determined. The authors reported no residual symptoms in their pa-
tients, however, and one can argue follow-up imaging of the popliteal
artery after repair of the aneurysm is unnecessary if the patient is
asymptomatic.
Inflammatory Abdominal Aortic Aneurysm: Predictors of Long-Term
Outcome in a Case-Control Study
Yusuf K, Murat B, Unal A, et al. Surgery 2007;141:83-9.
Conclusion: Persistent signs of inflammation after repair of an
inflammatory abdominal aortic aneurysm (IAAA), with or without retro-
peritoneal fibrosis, place a patient with IAAA at high risk for poor,
long-term outcome.
Summary: The authors sought to determine which features play a
role in determining long-term outcome in patients with IAAA. IAAA was
present in 17 of 238 patients (7.1%) who were operated for AAA from
1990 to 1997 at the authors’ institution. The patients with IAAA were
matched with a group of 35 patients with noninflammatory AAAs for age,
gender, and preoperative risk factors. Risk-factor analysis was determined
for poor outcome in the patients with IAAA vs those with noninflamma-
tory AAA.
Operations were performed through a midline incision. Clinical char-
acteristics and preoperative risk factors in the patients with AAA vs those
with IAAA were not significantly different. All patients with IAAA were
symptomatic. Patients with IAAA had larger aneurysms compared with
those with noninflammatory AAA (8.2 1.2 cm vs 6.1 0.4 cm, P .04).
The preoperative erythrocyte sedimentation rate was elevated in the patients
with IAAA compared with those with noninflammatory AAA (mean, 48 
14 mm/h vs 8  3 mm/h, P  .01). There was no difference in surgical
morbidity, mortality, intensive care unit, or hospital stay in the inflammatory
vs the noninflammatory AAA groups. Survival at 8 years was worse in the
inflammatory vs noninflammatory AAA group (60% vs 74%, P .01). A high
sedimentation rate after surgical intervention (P .02), presence of cardio-
vascular disease (P .01), and postoperative chronic renal failure (P .02)
were all independent risk factors for death in the IAAA group. No other
variables analyzed were statistically positive for adversely affecting long-term
mortality.
Comment: The two interesting features of this report are, first of all,
that despite similar preoperative morbidity and mortality, long-term mor-
tality in patients with IAAA appears to be greater than that of patients with
noninflammatory AAA, and this mortality is associated with signs of persist-
ing inflammation. Closer postoperative follow-up may be warranted in
patients with IAAA treated by open surgical reconstruction than for patients
treated for noninflammatory AAA.
Comparison of Risk-Adjusted 30-Day Postoperative Mortality and
Morbidity in Department of Veterans Affairs Hospitals and Selected
University Medical Centers: Vascular Surgical Operations in Men
Hutter MM, Lancaster RT, Henderson WG, et al. J Am Coll Surg 2007;
204:1115-26.
Conclusion: Risk-adjusted 30-day morbidity for vascular surgical op-
erations inmen is lower in Veterans Affairs (VA) hospitals compared with the
private sector. There is no difference in risk-adjusted mortality rates between
the two types of institution.
Summary: A congressional mandate required risk-adjusted surgical
outcomes in Department of Veterans Affairs hospitals to be compared with
those of private sector hospitals. In this regard, the National Surgical Quality
Improvement Program (NSQIP) was initiated in the VA system and then
extended to a group of university medical centers in the private sector. The
authors performed a risk-adjusted outcome analysis of vascular surgical
operations performed in men in VA hospitals compared with the university
private sector medical centers. The study design was a prospective cohort
study of vascular surgical operations in men from 128 VA medical centers
compared with 14 university medical centers. Procedures were performed
between October 1, 2001, and September 30, 2004. The study compared
patient and operative characteristics and unadjusted and adjusted 30-day
morbidity and mortality.
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